Robbins LLP Is Investigating the Officers and Directors of MiMedx Group, Inc. (MDXG) on Behalf of Shareholders
Robbins LLP is investigating whether certain officers and directors of MiMedx Group, Inc. (NasdaqCM: MDXG) violated federal securities laws. MiMedx, a biopharmaceutical company, develops and markets placenta-derived healing products.
MiMedx is the Focus of an Investigation by the U.S. Securities and Exchange Commission
On September 20, 2017, market research group Aurelius Value issued a report alleging that MiMedx may be under investigation by the U.S. Securities and Exchange Commission (“SEC”) and that MiMedx was engaging in undiscounted channel stuffing and suffering from kickback risks. Another market research group, Viceroy Research, similarly reported that several former MiMedx employees have accused the company of aggressive channel stuffing practices and improper revenue recognition policies. On September 21, 2017, MiMedx admitted that it was working with the SEC in its investigation. On this news, MiMedx stock fell $0.89 per share to close at $12.27 per share on September 21, 2017.
MiMedx Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact us via the form below and we will contact you directly.